HAS2 and cancer: As elevated levels of stromal HA transduce pro-angiogenic and tumorigenic signals in a multitude of other cancer types, including breast, prostate, ovarian, and lung (217), the therapeutic benefits of targeting HAS2 via autophagic degradation in these cancer types should be explored.